Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: A secondary analysis of data from the genome-based therapeutic drugs for depression (GENDEP) study

Journal of Clinical Psychiatry

Volumn 72, Issue 11, 2011, Pages 1478-1484

  Uher, Rudolf ^a   Mors, Ole ^b   Rietschel, Marcella ^c   Rajewska Rager, Aleksandra ^d   Petrovic, Ana ^e   Zobel, Astrid ^f   Henigsberg, Neven ^g   Mendlewicz, Julien ^h   Aitchison, Katherine J ^a   Farmer, Anne ^a   McGuffin, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^e NATIONAL INSTITUTE OF PUBLIC HEALTH   (Slovenia)

^f UNIVERSITY OF BONN   (Germany)

^g UNIVERSITY OF ZAGREB   (Croatia)

^h FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; NORTRIPTYLINE;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG RESPONSE; HUMAN; ILLNESS TRAJECTORY; LONGITUDINAL LATENT CLASS ANALYSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; STATISTICAL ANALYSIS;

EID: 81755166016     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m06419     Document Type: Article

References (38)

1. Perroud N, Uher R, Marusic A, et al. Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trial. BMC Med. 2009;7(1):60. doi:10.186/1741-7015-7-60 PubMed
2. Zisook S, Trivedi MH, Warden D, et al. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study. J Affect Disord. 2009;117(1-2):63-73. doi:10.1016/j.jad.209.01.02 PubMed
3. Quitkin FM, Rabkin JG, Ross D, et al. Identification of true drug response to antidepressants: use of pattern analysis. Arch Gen Psychiatry. 1984;41(8):782-786. PubMed (Pubitemid 14092257)
4. Quitkin FM, McGrath PJ, Stewart JW, et al. Can the effects of antidepressants be observed in the first two weeks of treatment? Neuropsychopharmacology. 1996;15(4):390-394. doi:10.1016/0893-13X(95)0272-F PubMed
5. Bauer M, Bschor T, Pfennig A, et al.; WFSBP Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry. 2007; 8(2):67-104. doi:10.1080/ 156297070127829 PubMed (Pubitemid 46690921)
6. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22(4):343-396. doi:10.17/026981070841 PubMed (Pubitemid 351989984)
7. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults, 3: pharmacotherapy. J Affect Disord. 2009;117(suppl 1):S26-S43. doi:10.1016/j.jad.209.06.041 PubMed
8. Katz MM, Koslow SH, Frazer A. Onset of antidepressant activity: reexamining the structure of depression and multiple actions of drugs. Depress Anxiety. 1996-1997-1997;4(6):257-267. doi:10.102/(SICI)1520-6394(196)4: 6〈257:AID-DA1〉3.0.CO;2-9 PubMed
9. Papakostas GI, Petersen T, Sklarsky KG, et al. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatry Res. 2007;149(1-3):195-200. doi:10.1016/j.psychres.206.03. 014 PubMed (Pubitemid 46108106)
10. Szegedi A, Müller MJ, Anghelescu I, et al. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry. 2003;64(4):413-420. doi:10.408/JCP.v64n0410 PubMed (Pubitemid 36547285)
11. Szegedi A, Jansen WT, van Willigenburg AP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70(3):344-353. doi:10.408/JCP.07m03780 PubMed
12. Taylor MJ, Freemantle N, Geddes JR, et al. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry. 2006;63(11):1217-1223. doi:10.101/archpsyc. 63.1.1217 PubMed (Pubitemid 44708080)
13. Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? a meta-analysis. J Clin Psychiatry. 2005;66(2):148-158. doi:10.408/JCP.v6n0201 PubMed (Pubitemid 40314320)
14. Nierenberg AA, Farabaugh AH, Alpert JE, et al. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry. 2000;157(9):1423-1428. doi:10.176/api.ajp.157.9.1423 PubMed
15. Stassen HH, Angst J, Hell D, et al. Is there a common resilience mechanism underlying antidepressant drug response? evidence from 2848 patients. J Clin Psychiatry. 2007;68(8):1195-1205. doi:10.408/JCP.v68n0805 PubMed (Pubitemid 47395621)
16. Muthén B, Shedden K. Finite mixture modeling with mixture outcomes using the EM algorithm. Biometrics. 1999;55(2):463-469. doi:10.1/j.06-341X.19. 0463.x PubMed (Pubitemid 29302570)
17. McLachlan GJ, Peel D. Finite Mixture Models. New York, NY: John Wiley & Sons; 2000.
18. Muthén B, Brown H, Hunter AM, et al. General approaches to analysis of course: Applying growth mixture modeling to randomized trials of depression medication. In: Shrout PE, Keyes KM, Ornstein K, eds. Causality and Psychopathology: Finding the Determinants of Disorders and their Cures. New York, New York: Oxford University Press; 2011:159-178.
19. Cinar S, Oude Voshaar RC, Janzing JG, et al. The course of depressive symptoms in unipolar depressive disorder during electroconvulsive therapy: a latent class analysis. J Affect Disord. 2010;124(1-2):141-147. doi:10.1016/j.jad.209.1.02 PubMed
20. Hunter AM, Muthén BO, Cook IA, et al. Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder. J Psychiatr Res. 2010;44(2):90-98. doi:10.1016/j. jpsychires.209.06.06 PubMed
21. Muthén B, Brown HC. Estimating drug effects in the presence of placebo response: causal inference using growth mixture modeling. Stat Med. 2009; 28(27):3363-3385. PubMed doi:10.102/sim.3721
22. Stulz N, Thase ME, Klein DN, et al. Differential effects of treatments for chronic depression: a latent growth model reanalysis. J Consult Clin Psychol. 2010;78(3):409-419. doi:10.1037/a019267 PubMed
23. Uher R, Muthén B, Souery D, et al. Trajectories of change in depression severity during treatment with antidepressants. Psychol Med. 2010;40(8): 1367-1377. doi:10.1017/S032917091528 PubMed
24. Wing JK, Sartorius N, Ustin TB. Diagnosis And Clinical Measurement in Psychiatry: A Reference Manual for SCAN. Geneva, Switzerland: World Health Organization; 1998.
25. Uher R, Maier W, Hauser J, et al. Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br J Psychiatry. 2009; 194(3):252-259. doi:10.192/bjp.bp.108.05754 PubMed
26. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389. doi:10.192/bjp.134.4.382 PubMed (Pubitemid 9136500)
27. Uher R, Farmer A, Maier W, et al. Measuring depression: comparison and integration of three scales in the GENDEP study. Psychol Med. 2008;38(2): 289-300. doi:10.1017/S0329170701730 PubMed (Pubitemid 351156595)
28. Muthén LK, Muthen BO. Mplus User's Guide: Statistical Analysis With Latent Variables. 5th ed. Los Angeles, CA: Muthén & Muthén; 2008.
29. Muthén B, Asparouhov T. Growth mixture modeling: Analysis with non-Gaussian random effects. In: Fitzmaurice G, Davidian M, Verbeke G, et al., eds. Longitudinal Data Analysis. Boca Raton, FL: Chapman & Hall/CRC Press; 2008:143-165.
30. Raftery AE. Bayesian model selection in social research. Sociol Methodol. 1995;25:111-163. doi:10.2307/271063
31. Schwarz G. Estimating the dimension of a model. Ann Stat. 1978;6(2):461-464. doi:10.1214/aos/17634136
32. Nylund KL, Asparouhov T, Muthen BO. Deciding on the number of cases in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. Struct Equ Modeling. .2007;14:535-569.
33. Celeux G, Soromenho G. An entropy criterion for assessing the number of clusters in a mixture model. J Classification. 1996;13(2):195-212. doi:10.107/BF01246098
34. Lieberman JA, Greenhouse J, Hamer RM, et al. Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology. 2005;30(3):445-460. doi:10.1038/sj.np.130571 PubMed (Pubitemid 40271148)
35. StataCorp. Stata Statistical Software: Release 10. College Station, TX: Stata Corp LP; 2007.
36. Leuchter AF, Cook IA, Gilmer WS, et al. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Res. 2009;169(2):132-138. doi:10.1016/j.psychres.209.04.04 PubMed
37. Lane P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm Stat. 2008;7(2):93-106. doi:10.102/pst.267 PubMed (Pubitemid 351943638)
38. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat. 2001;11(1-2):9-21. doi:10.1081/BIP- 10104194 PubMed (Pubitemid 32642825)